▼ FUTURE STUDENTS

▼ CURRENT STUDENTS

▼ ACADEMICS & RESEARCH

▼ DEPARTMENTS

▼ CAMPUS SERVICES

▼ eResources

Grenfell Campus
Menu Button
Close
Default Interior

Dr. Michael Grant

Funding Opportunities

Dr. Michael Grant.jpgDr. Michael Grant
Associated Professor
Faculty of Medicine

Dr. Grant was awarded a 2019 ARC-NL Research Grant for his project entitled, Vaccination to Reduce Age-Related Morbidity.

ARC-NL: What piqued your interest in this area of research?
I have studied the immunology of human immunodeficiency virus infection for over 30 years.  With greatly improved antiviral treatments through that time, a syndrome of accelerated aging has emerged as a major clinical problem.  This syndrome is linked with cytomegalovirus infection and accumulation of senescent cells.  In a number of different experimental systems, including natural aging, elimination of senescent cells is beneficial to health.

ARC-NL: Can you please provide a brief synopsis of your specific project? 
A new class of drugs termed senolytics is under development to eliminate senescent cells and promote healthy aging.  So far, these drugs are fairly non-specific, non-potent and cause some side effects.  Senescent cells express a protein, p16Ink4a, that can be targeted by the immune system when expressed in cervical cancer cells.  Our project involves stimulating the immune system against p16Ink4a as a way to eliminate senescent cells.  We previously identified T cells specific for cytomegalovirus as the circulating lymphocytes closest to senescence, so focused on these cells to investigate expression of p16Ink4a and susceptibility to immune recognition.  
     
ARC-NL: How did getting the support of the ARC-NL Research Grant assist you with your project?
Support from ARC-NL allowed me to move forward to purchase the specific materials required to obtain preliminary results for this project.   
 
ARC-NL: How do you feel your research will benefit the aging population of Newfoundland and Labrador? Canada?
I am confident the field of senolytic therapy will ultimately benefit healthy aging in humans.  Our approach of training one’s own immune system to eliminate senescent holds promise to reduce side-effects and provide greater versatility compared to current senolytic drugs. 

ARC-NL: Is there any past experience that you feel is pertinent to your success today? 
I believe the accelerated aging syndrome in persons living with human immunodeficiency virus has a mechanism overlapping with unhealthy aging in the general population.  



Aging Research Centre (ARC)

Grenfell Campus, Memorial University of Newfoundland
20 University Drive, Corner Brook, Newfoundland
A2H 5G4, Canada

Office: FC4022
Phone: 709-639-4872
Email: arc@grenfell.mun.ca



Grenfell Logo

© Grenfell Campus, Memorial University of Newfoundland, Corner Brook, NL Canada Toll Free 1-888-637-6269

Privacy Policy    Login    Library    Sitemap    Site Feedback    Contact

Grenfell Logo

© Grenfell Campus, Memorial University of Newfoundland, Corner Brook, NL Canada. Toll Free 1-888-637-6269


Privacy Policy

Login

Library

Sitemap

Site Feedback

Contact